Peptides 101 with Jay Campbell: Healing Hormones and Human Optimization Explained

Jay Campbell Has Been in the Peptide Trenches Longer Than Most

Jay Campbell is a polarizing figure in the health optimization world. He is a bestselling author on testosterone optimization and has been publicly documenting his personal use of peptides for years. In this conversation with Cody McBroom, he covers peptide therapy from the perspective of someone who has more than studied the research but has been a patient and self-experimenter. That dual lens produces insights you will not get from a purely academic discussion.

Campbell starts with something that needs to be said more often: the peptide space is messy. There is real science behind these molecules, genuine clinical data, and experienced doctors getting good results with patients. There is also rampant misinformation, sketchy suppliers selling impure products, and social media influencers recommending compounds they barely understand. Navigating this requires skepticism and effort.

He frames peptides as part of what he calls "human optimization," a broader philosophy that includes hormone management, nutrition, training, sleep, and stress reduction. Peptides, in his view, are precision tools that fill specific gaps, not a replacement for the fundamentals. This is a recurring theme in serious peptide conversations, and it is worth repeating because so many people are looking for the injectable version of a shortcut.

The Hormone-Peptide Connection Campbell Keeps Returning To

Campbell has written extensively about testosterone replacement therapy, and he sees peptides as a natural extension of hormone optimization. His argument: your hormonal environment determines how well your body responds to everything else, from training to nutrition to peptides themselves. A man with testosterone levels of 250 ng/dL (low) will not get the same benefit from a growth hormone secretagogue as a man at 700 ng/dL. The hormonal foundation needs to be in place first.

For growth hormone optimization, Campbell uses Ipamorelin and CJC-1295 as his baseline protocol. He has been consistent about this recommendation for years, which adds credibility. His typical approach is subcutaneous injection of both peptides before bed, five days per week. He tracks IGF-1 levels and adjusts dosing based on lab work, aiming for the upper quartile of the reference range without exceeding it.

He reports improved sleep quality as the first noticeable effect, usually within the first week. Fat loss, particularly around the midsection, follows over 4-8 weeks. Recovery from training improves, and skin quality gets better, something that is cosmetic but often noticed by patients before they see body composition changes. These observations align with what most peptide clinicians report and match the expected physiological effects of optimized growth hormone levels.

On the testosterone side, Campbell has used Gonadorelin (a GnRH analog) as part of his TRT protocol to maintain testicular function and fertility. This is a peptide approach to a common TRT concern: exogenous testosterone suppresses natural production and can cause testicular atrophy. Gonadorelin stimulates the pituitary to release LH and FSH, preserving some degree of natural testosterone production and testicular volume while on TRT.

Healing Peptides: Campbell on BPC-157 and More

Campbell is a vocal advocate for BPC-157, and he shares several personal experiences with injury recovery. He describes healing a long-standing shoulder injury with a BPC-157/TB-500 combination over six weeks, something he says conventional treatments had not resolved over years. This is anecdotal, obviously, and he acknowledges that. But his experience matches what many practitioners and patients report.

He goes deeper into the gut-brain connection with BPC-157 than most conversations do. BPC stands for Body Protection Compound, and it was originally isolated from gastric juice. Campbell argues that its gut-healing properties may be as important as its musculoskeletal effects, particularly for people with chronic gut inflammation, leaky gut, or autoimmune GI conditions. The theory is that systemic inflammation often originates in the gut, and by healing the gut lining, BPC-157 may reduce inflammation throughout the body.

TB-500, he explains, works synergistically with BPC-157 because they attack healing from different angles. BPC-157 promotes blood vessel growth to the injury site and upregulates growth factor receptors. TB-500 facilitates cell migration, bringing repair cells to where they are needed. Together, they cover more of the healing cascade than either one alone.

Campbell also discusses KPV, a smaller peptide fragment derived from alpha-MSH (alpha-melanocyte stimulating hormone), which has anti-inflammatory and antimicrobial properties. He uses it primarily for gut inflammation and reports positive results, though the published data on KPV is even more limited than BPC-157. It is available as an oral capsule, which makes it more accessible for people who are not comfortable with injections.

The Regulatory Crackdown: What It Means for Patients

A significant portion of the conversation addresses the FDA crackdown on compounded peptides that intensified in 2023 and 2024. Campbell is candid about his frustration. Several peptides that were widely available through compounding pharmacies have been restricted or removed from the compounding bulk substance list. This has reduced access for patients who were getting real benefit from these therapies.

His take, which is shared by many in the peptide community, is that regulatory pressure is at least partly driven by pharmaceutical industry interests. As major pharma companies develop their own peptide drugs (GLP-1 agonists being the most obvious example), there is a financial incentive to restrict compounded alternatives. Whether you agree with that framing or not, the practical reality is that access to many peptides has become more difficult.

Campbell advises patients to work with physicians who have established relationships with reputable compounding pharmacies and who can navigate the evolving regulatory space. He also suggests that patients educate themselves on which peptides are still legally available through compounding and which have been restricted, as the situation changes frequently.

The Mindset Piece That Gets Overlooked

One section of the conversation that stands out is Campbell discussion of mindset and stress management. He argues that chronic psychological stress undermines every biological optimization strategy. Elevated cortisol suppresses growth hormone, disrupts testosterone production, promotes visceral fat storage, and impairs immune function. No peptide protocol can overcome a nervous system that is stuck in chronic fight-or-flight mode.

His recommendations here are practical: daily meditation or breathwork (even 10 minutes), cold exposure, regular time in nature, and setting boundaries around work and technology. These are not novel suggestions, but hearing them from someone known for his peptide and hormone expertise shows how fundamental they are. The best protocol in the world fails if you are sleeping five hours a night and chronically stressed.

Getting Started Without Going Off the Deep End

For someone new to peptides, Campbell offers a reasonable roadmap. Step one: get thorough blood work done. This includes a full hormone panel (total and free testosterone, estradiol, SHBG, thyroid panel, cortisol), metabolic markers (fasting insulin, glucose, HbA1c), inflammatory markers (hsCRP), and IGF-1. These numbers tell you where your baseline is and help identify whether hormone optimization should come before or alongside peptide therapy.

Step two: find a qualified practitioner. Campbell recommends looking for doctors affiliated with the International Peptide Society or those who have completed fellowship training in anti-aging or regenerative medicine. Ask about their clinical experience with peptides specifically, more than their general credentials.

Step three: start with one protocol targeting your primary concern. Do not stack five peptides in your first month. If sleep and recovery are your main issues, try a GH secretagogue protocol alone for 8-12 weeks and evaluate. If you have a specific injury, run a healing peptide cycle for 4-6 weeks. Build your experience gradually.

Step four: retest blood work at 8-12 weeks and adjust based on results. This is not optional. Without lab data, you are guessing. And in a space with real quality control concerns around peptide sourcing, lab results are your only objective measure of whether the product is doing what it should.

Campbell brings energy and real-world experience to a conversation that sometimes gets stuck in theoretical territory. His willingness to share personal results, including what has not worked, makes the discussion more practical than most. Paired with proper medical guidance and lab monitoring, the approach he outlines is sensible and grounded.

Clinical Data Supporting the Peptides Campbell Recommends

The growth hormone secretagogue combination Campbell uses has published support. A 2004 study in the Journal of Clinical Endocrinology and Metabolism tested CJC-1295 in healthy adults and found that a single subcutaneous dose produced sustained GH elevation lasting up to 6 days, with IGF-1 levels rising 1.5 to 3 fold above baseline. Ipamorelin, tested in a 2005 study in the European Journal of Endocrinology, was shown to selectively stimulate GH release without affecting cortisol, prolactin, or ACTH levels, making it one of the cleanest GH secretagogues available in terms of side effect profile. The combination of the two is popular among peptide clinicians because CJC-1295 provides sustained baseline GH elevation while Ipamorelin adds acute pulsatile release, mimicking the natural pattern of GH secretion more closely than either peptide alone.

For BPC-157, the gut-healing properties Campbell emphasizes are supported by animal research from the University of Zagreb. A 2001 study in Life Sciences showed that BPC-157 protected against NSAID-induced intestinal damage in rats and accelerated healing of existing lesions. A 2012 study in the Journal of Physiology and Pharmacology demonstrated that BPC-157 improved colonic anastomosis healing, suggesting it works across multiple sections of the GI tract. While human trial data is limited, a 2020 case series published by a US-based functional medicine group reported symptom improvement in 8 of 10 patients with inflammatory bowel conditions treated with BPC-157 over 8 weeks. These early signals support clinical use but underscore the need for larger controlled trials.